Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
PLoS ONE, July 2011 | Volume 6 | Issue 7 | e22273
The development of an effective malaria vaccine is regarded as one cornerstone in the fight against this deadly disease and to achieve its eventual elimination. Malaria vaccine development
is hindered by the fact that the parasite proceeds through a succession of stages in the human host, with stage specific expression of proteins, a high level of antigen polymorphism, redundancy of essential invasion pathways in host cells, and utilization of a number of immune evasion mechanisms.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children | Download |